4//SEC Filing
Duncan Jason 4
Accession 0000950170-25-022316
CIK 0001885522other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 4:30 PM ET
Size
11.1 KB
Accession
0000950170-25-022316
Insider Transaction Report
Form 4
Duncan Jason
See Remarks
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−400,000→ 0 totalExercise: $12.97Exp: 2033-12-11→ Common Stock (400,000 underlying) - Award
Stock Option (Right to Buy)
2025-02-13+500,000→ 500,000 totalExercise: $1.69Exp: 2035-02-13→ Common Stock (500,000 underlying) - Award
Stock Option (Right to Buy)
2025-02-13+400,000→ 400,000 totalExercise: $1.69Exp: 2033-12-11→ Common Stock (400,000 underlying)
Footnotes (4)
- [F1]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F2]25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F3]On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
- [F4]Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
Documents
Issuer
Neumora Therapeutics, Inc.
CIK 0001885522
Entity typeother
Related Parties
1- filerCIK 0001741553
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 4:30 PM ET
- Size
- 11.1 KB